My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

aTyr Pharma, Inc. - Common Stock (NQ:ATYR)

0.6838 -0.0232 (-3.28%)

Streaming Delayed Price Updated: 12:55 PM EST, Jan 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about aTyr Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Nasdaq Gains Over 100 Points; Tesla Shares Spike Higher ↗

September 15, 2025

Via Benzinga

Why Is aTyr Stock Falling Today? ↗

September 15, 2025

Via Stocktwits

New Mountain Finance, Texas Instruments, Analog Devices And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

September 15, 2025

Via Benzinga

Why Check-Cap Shares Are Trading Higher By 183%; Here Are 20 Stocks Moving Premarket ↗

September 15, 2025

Via Benzinga

Why Is Atyr Pharma Stock Slipping Premarket? ↗

September 15, 2025

Investors braced for imminent Phase 3 EFZO-FIT trial results of efzofitimod, with analysts calling it a key inflection point.

Via Stocktwits

1 Small-Cap Biotech Stock Poised for a Breakout ↗

September 11, 2025

The next couple of weeks could reveal a great deal about this stock's prospects.

Via The Motley Fool

Nvidia To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Friday ↗

August 22, 2025

Via Benzinga

Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday ↗

July 28, 2025

Via Benzinga

Topics Artificial Intelligence

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 23, 2025

Via Benzinga

GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday ↗

July 23, 2025

Via Benzinga

These stocks are gapping in today's session ↗

July 23, 2025

The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

5 Biotech Stocks with Highly Anticipated Pending Results ↗

June 26, 2025

Via Stocktwits

Topics Intellectual Property

These stocks that are showing activity before the opening bell on Friday. ↗

April 25, 2025

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 25, 2025

Via Benzinga

Wondering what's happening in today's after-hours session? ↗

April 08, 2025

As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

What's going on in today's after hours session ↗

March 13, 2025

As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

March 13, 2025

From aTyr Pharma, Inc.

Via GlobeNewswire

Which stocks are gapping on Friday? ↗

March 07, 2025

In today's session, there are notable price gaps in the US markets on Friday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Earnings Scheduled For March 13, 2025 ↗

March 13, 2025

Via Benzinga

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

March 06, 2025

No safety concerns identified by independent data and safety monitoring board (DSMB), which recommends continuation of study without any modifications.

From aTyr Pharma, Inc.

Via GlobeNewswire

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

March 04, 2025

Management to host conference call and webcast on March 13th at 5:00 pm EDT / 2:00 pm PDT

From aTyr Pharma, Inc.

Via GlobeNewswire

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025

From aTyr Pharma, Inc.

Via GlobeNewswire

This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

February 18, 2025

Via Benzinga

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

January 29, 2025

From aTyr Pharma, Inc.

Via GlobeNewswire

This Toast Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

January 06, 2025

Via Benzinga

aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 17, 2024

From aTyr Pharma, Inc.

Via GlobeNewswire

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

December 12, 2024

From aTyr Pharma, Inc.

Via GlobeNewswire

aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

December 10, 2024

Independent data and safety monitoring board (DSMB) review includes all 268 patients who have been enrolled in the study and recommends continuation of study without any modifications.

From aTyr Pharma, Inc.

Via GlobeNewswire

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

December 09, 2024

ATYR0101 interacts with LTBP-1 to induce myofibroblast apoptosis through a novel anti-fibrotic mechanism to reduce fibrosis and fibrotic markers in models of lung and kidney fibrosis.

From aTyr Pharma, Inc.

Via GlobeNewswire

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

November 15, 2024

From aTyr Pharma, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.